PDF-European Medicines Agency Preauthorisation Evaluation of Medicines fo

Author : wang | Published Date : 2022-10-27

CHMP GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR HORMONE REPLACEMENT THERAPY OF OESTROGEN DEFICIENCY SYMPTOMS IN POSTMENOPAUSAL WOMEN DRAFT AGREED

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "European Medicines Agency Preauthorisati..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

European Medicines Agency Preauthorisation Evaluation of Medicines fo: Transcript

CHMP GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR HORMONE REPLACEMENT THERAPY OF OESTROGEN DEFICIENCY SYMPTOMS IN POSTMENOPAUSAL WOMEN DRAFT AGREED BY THE EFFICACY WORKING PARTY. 4420 74 18 84 00 Fax 4420 74 18 84 09 Email mailemeaeuropaeu httpwwwemeaeuropaeu EMEA 2008 Reproduction andor distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged London 11 December 2007 CPMP 4420 74 18 84 00 Fax 4420 74 18 85 45 Email mailemeaeuropaeu http wwwem eaeuropaeu EMEA 2007 Reproduction andor distribution of this document is authoris ed for non commercial purposes only provided the EMEA is acknowledged London 19 July 2007 Doc R 4420 74 18 84 00 Fax 4420 75 23 70 51 Email mailemeaeuropaeu httpwwwemeaeuropaeu EMEA 2007 Reproduction andor distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged London 26 October 2006 Doc R GUIDELINE ON THE LIMITS OF GENOTOXIC IMPURITIES DISCUSSION IN THE SAFETY WORKING PARTY DEADLINE FOR COMMENTS DISCUSSION IN THE SAFETY WORKING PARTY AND QUALITY WORKING PARTY June 2003 - February (CHMP) GUIDELINE ONTHE CHOICE OF THE NON-INFERIORITY MARGIN DRAFT AGREED BY THE EFFICACY WORKING PARTY ADOPTION BY COMMITTEE FOR RELEASE FOR CONSULTATION February 2004 AGREED BY WORKING PARTY June European Medicines Agency www.ema.europa .eu Heads of Medicines Agencies www.hma.eu The European Medicines Agency is an agency of the European Union (CHMP) SEALANT/HAEMOSTATIC PRODUCTS (CPMP/BPWG/153/00) DISCUSSION IN THE BLOOD PRODUCTS WORKING GROUP DISCUSSION IN THE PHARMACOVIGILANCE WORKING PARTY April 2001 TRANSMISSION TO THE CPMP Decembe GUIDELINE ON THE LIMITS OF GENOTOXIC IMPURITIES DISCUSSION IN THE SAFETY WORKING PARTY DEADLINE FOR COMMENTS DISCUSSION IN THE SAFETY WORKING PARTY AND QUALITY WORKING PARTY June 2003 - February Joint Audit Programme for EEA GMP Inspectorates 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 95 E-mail: gmp@emea.europa.eu http://www.emea. Joint Audit Programme for EEA GMP Inspectorates 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 95 E-mail: gmp@emea.europa.eu http://www.emea. (COMMITTEE ABBREVIATION) GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS DRAFT AGREED BY BWP May 2006 ADOPTION BY CHMPFOR RELEASE FOR CONSULTATION 28 Ju COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE ON DECLARATION OF HERBAL SUBSTANCES AND HERBAL PREPARATIONS IN HERBAL MEDIC Joint Audit Programme for EEA GMP Inspectorates 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 95 E-mail: gmp@emea.europa.eu http://www.emea. Answers to Knowledge Check in the post-event surveySME and academia Clinical Trials Information System CTIS two-part training webinar day 2Classified as public by the European Medicines Agency Europe

Download Document

Here is the link to download the presentation.
"European Medicines Agency Preauthorisation Evaluation of Medicines fo"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.